Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Moderate to severe pain Age: Adult Condition: Chronic pain, Immediate release |
Dose: Oral – 25 mg by mouth every morning initially Frequency: once daily Note: Dosage can be increased by 25-50 mg/day every 3 days up to 50-100 mg by mouth every 4-6 hours as needed; not to exceed 400 mg/day. |
|
Indication: Moderate to severe pain Age: Adult Condition: Acute pain, Immediate release |
Dose: Oral – 50-100 mg by mouth Frequency: every 4-6 hours as needed Note: Not to exceed 400 mg/day. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Moderate-to-Severe Pain Age: less than 17 years Condition: Immediate release |
Dose: Tablet – Dosage not established Note: Safety and efficacy not established |
|
Indication: Moderate-to-Severe Pain Age: greater than 17 years Condition: Acute, Immediate release |
Dose: Tablet – 50-100 mg Frequency: every 4-6 hours as needed Note: by mouth (oral); not to exceed 400 mg/day |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment with Creatinine Clearance 10-30 ml/min |
Dose: Dosage Form with Dose – Dosage Recommendation Frequency: every 12 hours Note: Increase dosing interval to 12 hourly |
|
Condition: Renal impairment with Creatinine Clearance less than 10 ml/min |
Dose: Dosage Form with Dose – Dosage Recommendation Note: Contraindicated |
Administration
- Can be taken with or without food
- Take at regular intervals as prescribed
Side Effect
- Constipation (24-46%)
- Nausea (24-40%)
- Dizziness (10-33%)
- Vertigo (26-33%)
- Headache (18-32%)
- Somnolence (7-25%)
- Vomiting (9-17%)
- Agitation (7-14%)
- Anxiety (7-14%)
- Emotional lability (7-14%)
- Euphoria (7-14%)
- Hallucinations (7-14%)
- Nervousness (7-14%)
- Spasticity (7-14%)
- Dyspepsia (5-13%)
- Asthenia (6-12%)
- Pruritus (8-11%)
- Diarrhea (5-10%)
- Dry mouth (5-10%)
- Sweating (6-9%)
- Hypertonia (1-5%)
- Malaise (1-5%)
- Menopausal symptoms (1-5%)
- Rash (1-5%)
- Urinary frequency (1-5%)
- Urinary retention (1-5%)
- Vasodilation (1-5%)
- Visual disturbance (1-5%)
- Abnormal gait
- Amnesia
- Cognitive dysfunction
- Depression
- Difficulty in concentration
- Dysphoria
- Dysuria
- Fatigue
- Hallucinations
- Menstrual disorder
- Motor system weakness
- Orthostatic hypotension
- Paresthesia
- Seizures
- Suicidal tendencies
- Syncope
- Tachycardia
- Tremor
- Abnormal electrocardiogram (ECG)
- Angioedema
- Bronchospasm
- Flushing
- Hypertension
- Hypotension
- Myocardial ischemia
- Palpitation
- Urticaria
- Withdrawal syndrome
- Respiratory depression
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
SSRI, serotonin-norepinephrine reuptake inhibitors (SNRI), TCA, other seizure threshold lowering drugs (e.g. bupropion, mirtazapine, tetrahydrocannabinol)
|
Increased risk of convulsions or serotonin syndrome
|
|
Carbamazepine
|
Decreased serum concentrations
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Suicidal Tendency/Acute Alcoholism
|
Risk of overdose
|
|
Head Injuries/Raised Intracranial Pressure
|
Can worsen brain condition
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.